DaVita Inc. (NYSE:DVA – Get Free Report) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 6,390,000 shares, a decline of 5.1% from the November 15th total of 6,730,000 shares. Based on an average trading volume of 1,350,000 shares, the days-to-cover ratio is currently 4.7 days. Currently, 7.1% of the shares of the stock are sold short.
Hedge Funds Weigh In On DaVita
Large investors have recently bought and sold shares of the business. BlackRock Inc. increased its position in shares of DaVita by 5.4% during the first quarter. BlackRock Inc. now owns 5,083,162 shares of the company’s stock worth $412,295,000 after acquiring an additional 260,783 shares in the last quarter. State Street Corp increased its position in shares of DaVita by 2.5% during the second quarter. State Street Corp now owns 2,606,222 shares of the company’s stock worth $261,847,000 after acquiring an additional 63,136 shares in the last quarter. Invesco Ltd. grew its position in DaVita by 21.3% in the third quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares in the last quarter. Norges Bank bought a new position in DaVita in the fourth quarter valued at $116,373,000. Finally, Morgan Stanley grew its position in DaVita by 37.9% in the fourth quarter. Morgan Stanley now owns 1,232,647 shares of the company’s stock valued at $92,042,000 after purchasing an additional 339,051 shares in the last quarter. 84.69% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently weighed in on the stock. TheStreet cut shares of DaVita from a “b-” rating to a “c” rating in a research note on Monday, October 23rd. Truist Financial decreased their price objective on shares of DaVita from $115.00 to $104.00 and set a “hold” rating on the stock in a research note on Wednesday, October 11th. UBS Group decreased their price objective on shares of DaVita from $142.00 to $113.00 and set a “buy” rating on the stock in a research note on Friday, November 17th. Finally, StockNews.com began coverage on shares of DaVita in a research note on Thursday, October 5th. They set a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $102.67.
DaVita Price Performance
Shares of DVA stock opened at $105.69 on Monday. DaVita has a 1 year low of $70.80 and a 1 year high of $116.97. The firm’s 50 day moving average is $90.27 and its 200-day moving average is $96.93. The firm has a market capitalization of $9.65 billion, a price-to-earnings ratio of 16.21, a PEG ratio of 0.74 and a beta of 1.09. The company has a current ratio of 1.24, a quick ratio of 1.19 and a debt-to-equity ratio of 6.01.
DaVita (NYSE:DVA – Get Free Report) last announced its earnings results on Tuesday, November 7th. The company reported $2.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.92 by $0.93. DaVita had a net margin of 5.11% and a return on equity of 63.38%. The company had revenue of $3.12 billion for the quarter, compared to analyst estimates of $3.02 billion. During the same period in the prior year, the business earned $1.45 earnings per share. DaVita’s quarterly revenue was up 5.9% on a year-over-year basis. Sell-side analysts forecast that DaVita will post 8.07 EPS for the current fiscal year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.